Peringatan Keamanan

There is no information available regarding the LD₅₀ and overdose of tauroursodeoxycholic acid.

Tauroursodeoxycholic acid

DB08834

small molecule approved investigational

Deskripsi

Tauroursodeoxycholic acid, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid ^A249070 that is produced in humans at a low concentration.^A249070 It is a taurine conjugate of ursodeoxycholic acid ^A249065 with comparable therapeutic efficacy and safety,^A249070 but a much higher hydrophilicity.^A249060 Normally, hydrophilic bile acids regulates hydrophobic bile acids and their cytotoxic effects. Tauroursodeoxycholic acid can reduce the absorption of cholesterol in the small intestine, thereby reducing the body's intake of dietary cholesterol and the body cholesterol content.^A249080

Tauroursodeoxycholic acid is currently used in Europe to treat and prevent gallstones as a bile acid derivative.^L17040 Due to a range of its molecular properties - namely its anti-apoptotic effects - tauroursodeoxycholic acid has been examined in inflammatory metabolic diseases and neurodegenerative diseases.A249065,A249070

Struktur Molekul 2D

Berat 499.71

Wujud solid

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi There is evidence that tauroursodeoxycholic acid crosses the blood brain barrier in humans.[A249065]

Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

There is little biotransformation of tauroursodeoxycholic acid. It is partially deconjugated by intestinal microflora to form unconjugated bile acids.A249095,A249100

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

176 Data

Lepirudin	The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Tauroursodeoxycholic acid.
Bivalirudin	The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Tauroursodeoxycholic acid.
Alteplase	The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Tauroursodeoxycholic acid.
Urokinase	The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Tauroursodeoxycholic acid.
Reteplase	The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Tauroursodeoxycholic acid.
Anistreplase	The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Tauroursodeoxycholic acid.
Tenecteplase	The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Tauroursodeoxycholic acid.
Drotrecogin alfa	The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Tauroursodeoxycholic acid.
Streptokinase	The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Tauroursodeoxycholic acid.
Dicoumarol	The risk or severity of bleeding and bruising can be increased when Dicoumarol is combined with Tauroursodeoxycholic acid.
Argatroban	The risk or severity of bleeding and bruising can be increased when Argatroban is combined with Tauroursodeoxycholic acid.
Ardeparin	The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Tauroursodeoxycholic acid.
Phenindione	The risk or severity of bleeding and bruising can be increased when Phenindione is combined with Tauroursodeoxycholic acid.
Fondaparinux	The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Tauroursodeoxycholic acid.
Warfarin	The risk or severity of bleeding and bruising can be increased when Warfarin is combined with Tauroursodeoxycholic acid.
Pentosan polysulfate	The risk or severity of bleeding and bruising can be increased when Pentosan polysulfate is combined with Tauroursodeoxycholic acid.
Phenprocoumon	The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Tauroursodeoxycholic acid.
Heparin	The risk or severity of bleeding and bruising can be increased when Heparin is combined with Tauroursodeoxycholic acid.
Enoxaparin	The risk or severity of bleeding and bruising can be increased when Enoxaparin is combined with Tauroursodeoxycholic acid.
Acenocoumarol	The risk or severity of bleeding and bruising can be increased when Acenocoumarol is combined with Tauroursodeoxycholic acid.
4-hydroxycoumarin	The risk or severity of bleeding and bruising can be increased when 4-hydroxycoumarin is combined with Tauroursodeoxycholic acid.
Coumarin	The risk or severity of bleeding and bruising can be increased when Coumarin is combined with Tauroursodeoxycholic acid.
Ximelagatran	The risk or severity of bleeding and bruising can be increased when Ximelagatran is combined with Tauroursodeoxycholic acid.
Desmoteplase	The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Tauroursodeoxycholic acid.
Ancrod	The risk or severity of bleeding and bruising can be increased when Ancrod is combined with Tauroursodeoxycholic acid.
Rivaroxaban	The risk or severity of bleeding and bruising can be increased when Rivaroxaban is combined with Tauroursodeoxycholic acid.
Sulodexide	The risk or severity of bleeding and bruising can be increased when Sulodexide is combined with Tauroursodeoxycholic acid.
Semuloparin	The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Tauroursodeoxycholic acid.
Idraparinux	The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Tauroursodeoxycholic acid.
Astaxanthin	The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Tauroursodeoxycholic acid.
Apixaban	The risk or severity of bleeding and bruising can be increased when Apixaban is combined with Tauroursodeoxycholic acid.
Otamixaban	The risk or severity of bleeding and bruising can be increased when Otamixaban is combined with Tauroursodeoxycholic acid.
Amediplase	The risk or severity of bleeding and bruising can be increased when Amediplase is combined with Tauroursodeoxycholic acid.
Dabigatran etexilate	The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Tauroursodeoxycholic acid.
Danaparoid	The risk or severity of bleeding and bruising can be increased when Danaparoid is combined with Tauroursodeoxycholic acid.
Dalteparin	The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Tauroursodeoxycholic acid.
Tinzaparin	The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Tauroursodeoxycholic acid.
(R)-warfarin	The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Tauroursodeoxycholic acid.
Ethyl biscoumacetate	The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Tauroursodeoxycholic acid.
Nadroparin	The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Tauroursodeoxycholic acid.
Ditazole	The risk or severity of bleeding and bruising can be increased when Ditazole is combined with Tauroursodeoxycholic acid.
Edoxaban	The risk or severity of bleeding and bruising can be increased when Edoxaban is combined with Tauroursodeoxycholic acid.
Sodium citrate	The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Tauroursodeoxycholic acid.
Dextran	The risk or severity of bleeding and bruising can be increased when Dextran is combined with Tauroursodeoxycholic acid.
Bemiparin	The risk or severity of bleeding and bruising can be increased when Bemiparin is combined with Tauroursodeoxycholic acid.
Parnaparin	The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Tauroursodeoxycholic acid.
Desirudin	The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Tauroursodeoxycholic acid.
Antithrombin Alfa	The risk or severity of bleeding and bruising can be increased when Antithrombin Alfa is combined with Tauroursodeoxycholic acid.
Protein C	The risk or severity of bleeding and bruising can be increased when Protein C is combined with Tauroursodeoxycholic acid.
Antithrombin III human	The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Tauroursodeoxycholic acid.
Letaxaban	The risk or severity of bleeding and bruising can be increased when Letaxaban is combined with Tauroursodeoxycholic acid.
Darexaban	The risk or severity of bleeding and bruising can be increased when Darexaban is combined with Tauroursodeoxycholic acid.
Betrixaban	The risk or severity of bleeding and bruising can be increased when Betrixaban is combined with Tauroursodeoxycholic acid.
Nafamostat	The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Tauroursodeoxycholic acid.
Monteplase	The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Tauroursodeoxycholic acid.
Gabexate	The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Tauroursodeoxycholic acid.
Fluindione	The risk or severity of bleeding and bruising can be increased when Fluindione is combined with Tauroursodeoxycholic acid.
Protein S human	The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Tauroursodeoxycholic acid.
Brinase	The risk or severity of bleeding and bruising can be increased when Brinase is combined with Tauroursodeoxycholic acid.
Clorindione	The risk or severity of bleeding and bruising can be increased when Clorindione is combined with Tauroursodeoxycholic acid.
Diphenadione	The risk or severity of bleeding and bruising can be increased when Diphenadione is combined with Tauroursodeoxycholic acid.
Tioclomarol	The risk or severity of bleeding and bruising can be increased when Tioclomarol is combined with Tauroursodeoxycholic acid.
Melagatran	The risk or severity of bleeding and bruising can be increased when Melagatran is combined with Tauroursodeoxycholic acid.
Saruplase	The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Tauroursodeoxycholic acid.
(S)-Warfarin	The risk or severity of bleeding and bruising can be increased when (S)-Warfarin is combined with Tauroursodeoxycholic acid.
Tocopherylquinone	The risk or severity of bleeding and bruising can be increased when Tocopherylquinone is combined with Tauroursodeoxycholic acid.
Dabigatran	The risk or severity of bleeding and bruising can be increased when Dabigatran is combined with Tauroursodeoxycholic acid.
Troxerutin	The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Tauroursodeoxycholic acid.
Edetic acid	The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Tauroursodeoxycholic acid.
Reviparin	The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Tauroursodeoxycholic acid.
Dermatan sulfate	The risk or severity of bleeding and bruising can be increased when Dermatan sulfate is combined with Tauroursodeoxycholic acid.
SR-123781A	The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Tauroursodeoxycholic acid.
Abciximab	The risk or severity of adverse effects can be increased when Abciximab is combined with Tauroursodeoxycholic acid.
Eptifibatide	The risk or severity of adverse effects can be increased when Eptifibatide is combined with Tauroursodeoxycholic acid.
Ticlopidine	The risk or severity of adverse effects can be increased when Ticlopidine is combined with Tauroursodeoxycholic acid.
Anagrelide	The risk or severity of adverse effects can be increased when Anagrelide is combined with Tauroursodeoxycholic acid.
Clopidogrel	The risk or severity of adverse effects can be increased when Clopidogrel is combined with Tauroursodeoxycholic acid.
Tirofiban	The risk or severity of adverse effects can be increased when Tirofiban is combined with Tauroursodeoxycholic acid.
Pentoxifylline	The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Tauroursodeoxycholic acid.
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tauroursodeoxycholic acid.
Dipyridamole	The risk or severity of adverse effects can be increased when Dipyridamole is combined with Tauroursodeoxycholic acid.
Sulfinpyrazone	The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Tauroursodeoxycholic acid.
Cilostazol	The risk or severity of adverse effects can be increased when Cilostazol is combined with Tauroursodeoxycholic acid.
Ridogrel	The risk or severity of adverse effects can be increased when Ridogrel is combined with Tauroursodeoxycholic acid.
Epoprostenol	The risk or severity of adverse effects can be increased when Epoprostenol is combined with Tauroursodeoxycholic acid.
Resveratrol	The risk or severity of adverse effects can be increased when Resveratrol is combined with Tauroursodeoxycholic acid.
Nimesulide	The risk or severity of adverse effects can be increased when Nimesulide is combined with Tauroursodeoxycholic acid.
Tesmilifene	The risk or severity of adverse effects can be increased when Tesmilifene is combined with Tauroursodeoxycholic acid.
Defibrotide	The risk or severity of adverse effects can be increased when Defibrotide is combined with Tauroursodeoxycholic acid.
Beraprost	The risk or severity of adverse effects can be increased when Beraprost is combined with Tauroursodeoxycholic acid.
Ibudilast	The risk or severity of adverse effects can be increased when Ibudilast is combined with Tauroursodeoxycholic acid.
Andrographolide	The risk or severity of adverse effects can be increased when Andrographolide is combined with Tauroursodeoxycholic acid.
Caplacizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tauroursodeoxycholic acid.
Prasugrel	The risk or severity of adverse effects can be increased when Prasugrel is combined with Tauroursodeoxycholic acid.
Cangrelor	The risk or severity of adverse effects can be increased when Cangrelor is combined with Tauroursodeoxycholic acid.
Tranilast	The risk or severity of adverse effects can be increased when Tranilast is combined with Tauroursodeoxycholic acid.
Triflusal	The risk or severity of adverse effects can be increased when Triflusal is combined with Tauroursodeoxycholic acid.
Ticagrelor	The risk or severity of adverse effects can be increased when Ticagrelor is combined with Tauroursodeoxycholic acid.
Icosapent ethyl	The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Tauroursodeoxycholic acid.
Vorapaxar	The risk or severity of adverse effects can be increased when Vorapaxar is combined with Tauroursodeoxycholic acid.

Target Protein

Integrin alpha-5 ITGA5

Referensi & Sumber

Synthesis reference: Zhuo, Chao; Feng, Wei; Wu, Da-jun; Xiong, Zhi-gang. Synthesis of tauroursodeoxycholic acid. Hecheng Huaxue (2002), 10(5), 444-446.

Artikel (PubMed)

PMID: 8674405
Crosignani A, Battezzati PM, Setchell KD, Invernizzi P, Covini G, Zuin M, Podda M: Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. Dig Dis Sci. 1996 Apr;41(4):809-15. doi: 10.1007/BF02213140.
PMID: 24891994
Vang S, Longley K, Steer CJ, Low WC: The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases. Glob Adv Health Med. 2014 May;3(3):58-69. doi: 10.7453/gahmj.2014.017.
PMID: 32560070
Ahn TK, Kim KT, Joshi HP, Park KH, Kyung JW, Choi UY, Sohn S, Sheen SH, Shin DE, Lee SH, Han IB: Therapeutic Potential of Tauroursodeoxycholic Acid for the Treatment of Osteoporosis. Int J Mol Sci. 2020 Jun 16;21(12). pii: ijms21124274. doi: 10.3390/ijms21124274.
PMID: 33217585
Lu Q, Jiang Z, Wang Q, Hu H, Zhao G: The effect of Tauroursodeoxycholic acid (TUDCA) and gut microbiota on murine gallbladder stone formation. Ann Hepatol. 2021 Jul-Aug;23:100289. doi: 10.1016/j.aohep.2020.100289. Epub 2020 Nov 18.
PMID: 8675100
Setchell KD, Rodrigues CM, Podda M, Crosignani A: Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis. Gut. 1996 Mar;38(3):439-46. doi: 10.1136/gut.38.3.439.
PMID: 9918905
Invernizzi P, Setchell KD, Crosignani A, Battezzati PM, Larghi A, O'Connell NC, Podda M: Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. Hepatology. 1999 Feb;29(2):320-7. doi: 10.1002/hep.510290220.

Link

Contoh Produk & Brand

Produk: 2 • International brands: 2

Produk

Albrioza

Powder, for suspension • - • Oral • Canada • Approved
Relyvrio

Powder, for suspension • - • Oral • US • Approved

International Brands

Tauro — Teofarma
Taurolite — Bio-Gen

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.